Innovent Biologics (FRA:6IB) ROE % Adjusted to Book Value : -1.46% (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics ROE % Adjusted to Book Value?

Innovent Biologics's ROE % for the quarter that ended in Jun. 2024 was -6.28%. Innovent Biologics's PB Ratio for the quarter that ended in Jun. 2024 was 4.30. Innovent Biologics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was -1.46%.

Innovent Biologics ROE % Adjusted to Book Value Historical Data

The historical data trend for Innovent Biologics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics ROE % Adjusted to Book Value Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-6.42

-1.43

-5.76

-5.04

-1.90

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial											-4.49	-5.85	-0.66	-3.35	-1.46

Competitive Comparison of Innovent Biologics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Innovent Biologics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's ROE % Adjusted to Book Value falls into.

Innovent Biologics ROE % Adjusted to Book Value Calculation

Innovent Biologics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-8.62%	/	4.54
	=	-1.90%

Innovent Biologics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-6.28%	/	4.30
	=	-1.46%

Innovent Biologics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (FRA:6IB) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 01801:Hong Kong

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics Headlines

No Headlines